Varicella Zoster Virus Infection: Clinical Trials

268 completed, 43 recruiting, 40 unknown, 22 active not recruiting. 128 Phase 3, 83 Phase 2, 57 Not applicable, 53 Phase 4, 51 Phase 1.

By phase and status

Phase	Trials	Status
Phase 3	128	Completed 99, Recruiting 11, Unknown 9, Active not recruiting 3, Not yet recruiting 2, Terminated 2, Withdrawn 2
Phase 2	83	Completed 52, Recruiting 7, Active not recruiting 6, Not yet recruiting 6, Terminated 6, Unknown 4, Withdrawn 2
Not applicable	57	Completed 31, Recruiting 12, Unknown 8, Not yet recruiting 3, Active not recruiting 1, Terminated 1, Withdrawn 1
Phase 4	53	Completed 28, Unknown 11, Active not recruiting 3, Enrolling by invitation 3, Not yet recruiting 3, Recruiting 2, Terminated 2, Withdrawn 1
Phase 1	51	Completed 28, Active not recruiting 6, Recruiting 6, Terminated 4, Unknown 3, Not yet recruiting 2, Withdrawn 2
Early Phase 1	2	Completed 2

Follow Varicella Zoster Virus Infection: new trials by email Literature Review of Varicella Zoster Virus Infection trials Research Report on Varicella Zoster Virus Infection

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study Exploring the Effect of Adjuvanted RZV or RSVPreF3 Vaccines on Coronary Plaque Progression in Adults >=50 Years of Age at Risk for Cardiovascular Events Placebo, Adjuvanted RZV vaccine, Adjuvanted RSVPreF3 vaccine - Cardiovascular Disease	Phase 2	Not yet recruiting	GlaxoSmithKline	450	2026-10-23	2026-10-20
Comparative Study of Two Vaccination Schedules for the Subunit Herpes Zoster Vaccine in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disease Patients Treated With Anti-CD20 Therapy: an Open-label Randomised Controlled Trial Two-dose M0-M2 vaccination schedule, Two-dose M0-M6 vaccination schedule - Vaccine, Varicella-zoster Virus	Phase 4	Not yet recruiting	University Hospital, Toulouse	160	2026-10-20	2026-09-14
Shingrix in Patients With Rheumatic Diseases: a Double-blind Placebo-controlled RCT recombinant subunit herpes zoster vaccine - Herpes Zoster	Phase 4	Withdrawn	Tuen Mun Hospital		2026-09-29	2026-10-01
A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age MMRVNS vaccine, MMRV vaccine, DTaP-IPV vaccine - Measles, Mumps	Phase 3	Not yet recruiting	GlaxoSmithKline	1860	2026-08-11	2026-08-03
SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years NBP608 (Mid Potency), NBP608 (Low Potency), Varivax® - Varicella (Chickenpox)	Phase 3	Recruiting	SK Bioscience Co., Ltd.	780	2026-07-04	2026-09-15
Phase III Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above ABO1108, Placebo - Varicella-zoster Virus	Phase 3	Recruiting	Suzhou Abogen Biosciences Co., Ltd.	18000	2026-06-27	2026-09-14
Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children Varicella Vaccine - Varicella (Chickenpox), Varicella Immunisation	Phase 3	Not yet recruiting	Sinovac (Dalian) Vaccine Technology Co., Ltd.	300	2026-06-15	2026-06-12
A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age MMRVNS, MMRV - Measles, Measles-Mumps-Rubella+Chickenpox Vaccine	Phase 3	Recruiting	GlaxoSmithKline	1209	2026-05-11	2026-07-08
Efficacy and Safety of High-Concentration 35 kDa Hyaluronan Gel for Herpes Zoster-Associated Pain 10% High-Concentration 35 kDa Hyaluronan (HA35) Topical Analgesic Gel - Herpes Zoster, Zoster-Associated Pain	Not applicable	Completed	Nakhia Impex LLC	30	2026-05-01	2026-09-23
A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants HZ Vaccine (IN001), Shingrix - Herpes Zoster	Phase 2	Not yet recruiting	Shenzhen Shenxin Biotechnology Co., Ltd	480	2026-05-01	2025-10-07
Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia Recombinant Herpes Zoster Vaccine (Shingrix) - Cardiovascular Disease, Dementia	Phase 4	Active not recruiting	Tor Biering-Sørensen	168460	2026-04-28	2026-10-14
Clinical Features and Outcomes of VZV CNS Infections Varicella Zoster, Varicella Meningitis		Completed	Kocaeli University	59	2026-04-17	2026-10-07
Zoster Vaccine to Enhance Protection Against Zoster in Solid-organ Transplantation Booster dose of the recombinant zoster vaccine (RZV, Shingrix®) - Zoster; Herpes	Phase 2	Not yet recruiting	Oriol Manuel	75	2026-04-01	2026-03-02
Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above Shingrix, CVI-VZV-001 - Herpes Zoster	Phase 2	Not yet recruiting	Aribio Lab Co., Ltd.	135	2026-04-01	2026-03-19
A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland Recombinant zoster vaccine, Placebo - Herpes Zoster	Phase 4	Recruiting	GlaxoSmithKline	33609	2026-03-31	2026-05-12
A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years MG1111 (Barycela inj.), VARIVAX™ - Varicella (Chickenpox), Chickenpox Vaccine	Phase 3	Recruiting	GC Biopharma Corp	474	2026-03-17	2026-04-17
Long-term Effectiveness of the Live Attenuated Herpes Zoster Vaccine Attenuated Zoster Vaccine, Live, Matched Placebo Without Live Virus - Herpes Zoster		Recruiting	Jiangsu Province Centers for Disease Control and Prevention	24740	2026-03-06	2026-05-13
Second Dose of Varicella Vaccine in Healthy Children PROVARIX - Varicella (Chickenpox), Varicella Immunisation	Phase 3	Recruiting	Sinovac (Dalian) Vaccine Technology Co., Ltd.	300	2026-01-28	2026-03-16
Immunogenicity and Safety of SYS6017 in the Participants Aged 40 Years and Above A zoster mRNA vaccine SYS6017, Placebo, Active Comparator Vaccine - Herpes Zoster	Phase 2	Not yet recruiting	CSPC Megalith Biopharmaceutical Co.,Ltd.	800	2026-01-10	2026-01-21
Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine Low-dose experimental vaccine, High-dose experimental vaccine, Active-controlled vaccine A - Herpes Zoster, mRNA Vaccine	Phase 1 / Phase 2	Recruiting	Sinovac Biotech Co., Ltd	519	2026-01-06	2026-02-10

Showing 20 of 419. Sign in to see all of them.

Narrower conditions

Herpes Zoster (275)  ·  Chickenpox (169)  ·  Neuralgia, Postherpetic (54)  ·  Measles (45)  ·  Mumps (44)  ·  Rubella (44)  ·  Pain (30)  ·  Neuralgia (26)  ·  Herpes Simplex (13)  ·  HIV Infections (12)  ·  Peripheral Nervous System Diseases (9)  ·  Vaccine-Preventable Diseases (7)  ·  Virus Diseases (7)  ·  Arthritis, Rheumatoid (6)

Broader conditions

DNA Virus Infections (415)  ·  Herpesviridae Infections (413)  ·  Infections (413)  ·  Virus Diseases (412)  ·  Pathological Conditions, Signs and Symptoms (94)  ·  Nervous System Diseases (85)  ·  Signs and Symptoms (81)  ·  Neurologic Manifestations (78)  ·  RNA Virus Infections (71)  ·  Neuromuscular Diseases (65)  ·  Peripheral Nervous System Diseases (54)  ·  Stomatognathic Diseases (51)  ·  Mouth Diseases (50)  ·  Pain (46)

Interventions

Herpes Zoster Vaccine (50)  ·  Chickenpox Vaccine (28)  ·  measles, mumps, rubella, varicella vaccine (21)  ·  Valacyclovir (18)  ·  Measles-Mumps-Rubella Vaccine (12)  ·  Vaccines (12)  ·  Hepatitis A Vaccines (10)  ·  Saline Solution (8)  ·  Sodium Chloride (8)  ·  Pneumococcal Vaccines (6)  ·  Acyclovir (5)  ·  Data Collection (5)  ·  Famciclovir (5)  ·  Blood Specimen Collection (4)  ·  Gabapentin (4)

Sponsors

GlaxoSmithKline (73)  ·  Merck Sharp & Dohme LLC (51)  ·  Sinovac (Dalian) Vaccine Technology Co., Ltd. (16)  ·  Beijing Tiantan Hospital (11)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (11)  ·  NeurogesX (9)  ·  University of Colorado, Denver (6)  ·  MAXVAX Biotechnology Limited Liability Company (5)  ·  Sanofi Pasteur, a Sanofi Company (5)  ·  Shanghai Institute Of Biological Products (5)  ·  Asan Medical Center (4)  ·  Radboud University Medical Center (4)  ·  Seoul National University Hospital (4)  ·  Beijing Center for Disease Control and Prevention (3)  ·  Changchun Keygen Biological Products Co., Ltd. (3)

Countries

United States (122)  ·  China (70)  ·  South Korea (30)  ·  Germany (28)  ·  Canada (24)  ·  Italy (24)  ·  Czechia (19)  ·  France (19)  ·  Australia (16)  ·  Estonia (16)  ·  Spain (16)  ·  Taiwan (16)  ·  United Kingdom (15)  ·  Finland (14)  ·  Japan (12)

Top investigators

Jeffrey Tobias, MD (3)  ·  Nianmin Shi (3)  ·  Shengli Xia (3)  ·  Yanxia Wang (3)  ·  Alan Copa, PharmD (2)  ·  Annemette Hald, RN (2)  ·  Chi Chiu Mok (2)  ·  Fang Luo, M.D. (2)  ·  Freddy Caldera, DO (2)  ·  Hee-Jin Cheong, Ph.D (2)  ·  Hongxing Pan (2)

Results publications

PMID 37781954, PMID 36066965, PMID 37166199, PMID 40237463, PMID 40396505, PMID 27037091, PMID 29955836, PMID 30935742, PMID 31537443, PMID 32347767, PMID 32665955, PMID 32910152, PMID 33606577, PMID 10891827, PMID 12097537, PMID 12683413, PMID 12850341, PMID 15734076, PMID 15930418, PMID 15962639, PMID 16094218, PMID 16282339, PMID 16452343, PMID 1646585, PMID 16567978, PMID 16804432, PMID 17332177, PMID 17417658, PMID 17502347, PMID 18419349, PMID 18652095, PMID 18977178, PMID 19195785, PMID 19273678, PMID 19305145, PMID 19366435, PMID 19432499, PMID 19469706, PMID 19475609, PMID 19712037, PMID 19714266, PMID 20416263, PMID 20439572, PMID 20538187, PMID 20863322, PMID 20937130, PMID 20980796, PMID 21087403, PMID 21267044, PMID 21356040

NIH funding

2025 (5), 2015 (3), 2019 (3), 2005 (2), 2008 (2), 2009 (2), 2017 (2), 2018 (2), U19AI090023 (2), 2004 (1), 2014 (1), 2016 (1), 2023 (1), K23AG040708 (1), P01CA094237 (1)